ClinicalTrials.gg
RecruitingNCT07497789AIRC_ IG 34634Updated Nov 17, 2026

SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases

An observational study in CRC (Colorectal Cancer) and Liver Metastases From Colorectal Primary Cancer, sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 17, 2026Now RecruitingFirst site in Italy+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
156
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Planned enrollment
56th of 96
156 · median 258
Started
2026
with 11 others
Observational
96 of 429
33 open now
Primary completion
2027-07
later than 84 of 142 live
Registered
419th of 429
by date

Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 56th largest by planned enrollment of the 96 observational ones that give a count, is one of 12 that started in 2026, is one of 96 observational ones, reaches primary completion later than 84 of the 142 other live ones, and was the 419th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

97 more — sign in →

All 103 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK/mTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses

Read the detailed description

Colorectal cancer represents one of the leading causes of cancer-related mortality worldwide. A significant proportion of patients develop distant metastases during the course of the disease. Liver metastases are among the main causes of death in patients with colorectal cancer. Despite advances in the genetic characterization of colorectal carcinoma, the biological mechanisms that enable tumor cells to adapt to the hepatic microenvironment and establish metastases remain only partially understood. In particular, increasing evidence suggests that subpopulations of tumor cells with cancer stem cell-like properties play a key role in tumor progression, treatment resistance, and metastatic dissemination.

The study of tumor tissues directly derived from patients is a fundamental tool for understanding the molecular mechanisms underlying metastatic progression and for developing clinically relevant experimental models, such as primary cell cultures, spheroids, and tumor organoids.

The collection of tumor samples from patients undergoing surgical resection of primary colorectal cancer and/or hepatic metastases will allow molecular, cellular, and transcriptomic analyses aimed at identifying new potential therapeutic targets.

In this context, we aim to investigate the role of the methyltransferase SMYD3 in metabolic and oxidative stress adaptation mechanisms in colorectal cancer and its derived liver metastases. Indeed, SMYD3 has recently emerged as a significant oncogenic driver, overexpressed in several tumor types. Our recent studies have revealed its contribution to drug resistance in response to genotoxic stress. Targeting SMYD3, in combination with standard or targeted therapies, has shown promise in overcoming drug resistance across various cancer types, including colorectal carcinoma, supporting the integration of SMYD3 inhibition into cancer treatment regimens.

Moreover, we have identified several SMYD3-interacting partners implicated in molecular processes related to the hallmarks of cancer. Among these are AMPK and mTOR: AMPK acts as the cell's main metabolic guardian, rewiring energy fluxes to sustain survival under stress, while mTOR regulates anabolic growth in response to nutrient availability. In this context, SMYD3 emerges as a key factor mediating processes encompassed within two major functional clusters - one involved in DNA damage repair and the other in sustaining oncogenic signaling.

Our investigations into the involvement of SMYD3 in cancer progression have advanced through an extensive molecular and functional characterization of its role in the biology of cancer stem cells, as this population is responsible for chemoresistance, recurrence, and metastasis in colorectal carcinoma. We have demonstrated that SMYD3 inhibition or stable genetic ablation affects the clonogenic and self-renewal potential of cancer stem cells and patient-derived organoids by altering their molecular signature. Furthermore, we discovered that both stable ablation and pharmacological inhibition drastically reduce the metastatic potential of cancer stem cells, identifying SMYD3 as a promising therapeutic target acting directly on the oncogene c-MYC, with potential implications for counteracting cancer stem cell proliferation and metastatic spread.

Based on this novel role of SMYD3 in cancer stem cells and metastatic dissemination, this project aims to define its contribution to the reprogramming processes that enable metastatic cells to adapt to the hepatic microenvironment under new and stressful conditions. Therefore, by delineating SMYD3-dependent pathways that promote cancer stem cell survival in liver metastases, we aim to exploit their pharmacological vulnerabilities for the development of new therapeutic strategies integrating SMYD3 inhibitors with clinically available or experimental compounds targeting tumor metabolism and oxidative stress adaptation

03

Conditions studied

  • CRC (Colorectal Cancer)
  • Liver Metastases From Colorectal Primary Cancer

Keywords

  • Colorectal cancer
  • liver metastases
  • liver metastases from colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study is a multicenter prospective observational study and involves the collection of biological samples from patients undergoing surgery for CRC and/or liver metastases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Common criteria

  • Age ≥ 18 years.
  • Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes.
  • Signed written for the use of biological samples for research purposes.

Cohort/Arm 1 (Colon-rectal tumor resection)

- Patients undergoing surgical resection of colorectal cancer.

Cohort/Arm 2 (Primary tumor and liver resection) - Patients undergoing surgical resection of the primary colorectal tumor and liver metastases from colorectal carcinoma.

Cohort/Arm 3 (Liver metastases resection only)

- Patients undergoing surgical resection of liver metastases from colorectal carcinoma previously resected at the primary site.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Undergoing surgical intervention for a other than those specified in the inclusion criteria.
  • Lack of signed
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
156 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with CRC (colorectal cancer)

    Patients undergoing surgery for primary colorectal carcinoma, without liver metastases

  • Patients with colorectal cancer (CRC) and liver metastase

    Patients undergoing surgery for primary colorectal carcinoma who simultaneously present liver metastases from colorectal carcinoma. In this case, tissue samples will be taken from both the colorectal carcinoma and the liver metastases

  • Patients with liver metastase

    Patients undergoing surgery for the resection of liver metastases from previously operated colorectal cancer

06

What researchers measure

Primary outcomes

  1. Molecular and Cellular mechanisms

    Identification of the molecular and cellular mechanisms involved in metastatic progression that depend on the methyltransferase SMYD3

    Time frame: At the time of the surgery

07

Study locations

1 of 1 sites recruiting
  • IRCCS "S. de Bellis" - Medical Genetics
    Castellana Grotte, Bari 70013, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 12 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start May 2026 → Jul 2026, primary completion May 2027 → Jul 2027 and completion May 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
Jul 8, 2026was May 2026
Primary completionEst.
Jul 10, 2027was May 2027
CompletionEst.
Jul 10, 2028was May 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in Italy
Show site
  • IRCCS "S. de Bellis" - Medical Genetics · Castellana Grotte, Italy
Nov 17, 2026
Start date
May 10, 2026→Jul 8, 2026 (actual)
Nov 17, 2026
Primary completion
May 10, 2027→Jul 10, 2027
Nov 17, 2026
Study completion
May 10, 2028→Jul 10, 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Italy
    Show site
    • IRCCS "S. de Bellis" - Medical Genetics · Castellana Grotte, Italy
    Start date May 10, 2026→Jul 8, 2026 (now actual)
    Primary completion May 10, 2027→Jul 10, 2027
    Study completion May 10, 2028→Jul 10, 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07497789
Lead sponsor
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Collaborators
University of Bari
Responsible party
Cristiano Simone (Head of Medical Genetics, Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis) — Principal investigator
First posted
Mar 27, 2026
Start date
Jul 8, 2026
Primary completion
Jul 10, 2027 (estimated)
Completion
Jul 10, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Cristiano Simone, MD
Contact
cristiano.simone@irccsdebellis.it
+390804994615
Martina Lepore Signorile, Biologist
Contact
martina.lepore@irccsdebellis.it
+390804994615

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion